Key PointsAbbVie's treatment for patent-cliff woes is working and has the company on track to return to growth soon. Humira continues to outperform, and the non-Humira portfolio is more robust than expected. The pipeline is robust and amplified by recently announced acquisitions expected to close this year. 5 stocks we like better than AbbVieAbbVie NYSE: ABBV is turning an important corner in 2024 and is on track to resume growth. Its Humira-related patent cliff aside, the business is stronger than ever, an ...